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Tuberculosis is one of the leading causes of morbidity worldwide and the incidences of drug 
resistance and intolerance are prevalent. Thus, there is a desperate need for the development of 
new anti-tubercular drugs. Mycobacterium tuberculosis gyrase inhibitors (MGIs) are 
napthyridone/aminopiperidine-based drugs that display activity against M. tuberculosis cells and 
tuberculosis in mouse models [Blanco, D., et al. (2015) Antimicrob. Agents Chemother. 59, 
1868-1875]. Genetic and mutagenesis studies suggest that gyrase, which is the target for 
fluoroquinolone antibacterials, is also the target for MGIs. However, little is known regarding the 
interaction of these drugs with the bacterial type II enzyme. Therefore, we examined the effects 
of two MGIs, GSK000 and GSK325, on M. tuberculosis gyrase. MGIs greatly enhanced DNA 
cleavage mediated by the bacterial enzyme. In contrast to fluoroquinolones (which induce 
primarily double-stranded breaks), MGIs induced only single-stranded DNA breaks under a 
variety of conditions. MGIs work by stabilizing covalent gyrase-cleaved DNA complexes and 
appear to suppress the ability of the enzyme to induce double-stranded breaks. The drugs 
displayed little activity against type II topoisomerases from several other bacterial species, 
suggesting that these drugs display specificity for M. tuberculosis gyrase. Furthermore, MGIs 
maintain activity against M. tuberuclosis gyrase that contained the three most common 
fluoroquinolone resistance mutations seen in the clinic, but displayed no activity against human 
topoisomerase IIα. These findings suggest that MGIs have potential as anti-tubercular drugs, 
especially in the case of fluoroquinolone-resistant disease.  
 
KEYWORDS: gyrase, Mycobacterium tuberculosis gyrase inhibitors, fluoroquinolones, 
tuberculosis, single-stranded DNA cleavage  
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Tuberculosis is a lung infection caused by the bacterium Mycobacterium tuberculosis, an aerobic 
bacillus that stains neither Gram-positive nor Gram-negative.1 It is one of the leading causes of 
mortality worldwide and recently surpassed HIV/AIDS as the deadliest disease caused by a 
single infectious agent.2 In 2016, there were an estimated 10.4 million new cases of tuberculosis 
reported world-wide and 1.7 million people died from the disease. Of these reported cases, an 
estimated 490,000 were diagnosed with multi-drug resistant tuberculosis.3  
 The standard treatment regimen for tuberculosis includes rifampin, isoniazid, pyrazinamide, 
and ethambutol.1,4 However, fourth-generation fluoroquinolone antibacterials, such as 
moxifloxacin (Figure 1) and levofloxacin, are critical drugs for treating patients who have 
multidrug-resistant tuberculosis or are intolerant of first-line therapies.5 Unfortunately, 
fluoroquinolone resistance is on the rise and is starting to impact the treatment of tuberculosis.2 
In most cases, this resistance is caused by mutations in gyrase, a type II topoisomerase, which is 
the cellular target for these drugs.6-12 
 Most bacteria encode two type II topoisomerases, gyrase and topoisomerase IV.7, 10, 12-16 
These enzymes alleviate the torsional stress that accumulates in DNA ahead of replication forks 
and transcription complexes and remove knots and tangles from the genome, respectively.12-13, 15, 
17-22 They perform these tasks by creating a transient double-stranded DNA break in one DNA 
segment, passing a second DNA segment through the break, and ligating the broken segment.7, 10, 
15, 22 M. tuberculosis is unusual in that it encodes only gyrase, which carries out the cellular 
functions of both type II enzymes.23-25 Thus, it is an ideal antibacterial target for disrupting M. 
tuberculosis DNA replication and transcription. Fluoroquinolones act by stabilizing a covalent 
gyrase-cleaved DNA complex (cleavage complex) that is a requisite intermediate in the double-
stranded DNA passage reaction of the enzyme.6-12 This stabilization generates double-stranded 
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breaks in the bacterial chromosome, which induces the SOS response and can lead to eventual 
cell death.6-12  
 The lack of available drugs and the rising incidence of drug resistance and intolerance point 
to a need for the development of new antitubercular agents.2 Two approaches have been used to 
address this issue: the discovery of new antibacterial targets and the development of new drugs 
that act through validated targets, but do not succumb to current resistance patterns. Using this 
latter approach, a new class of naphthyridone/aminopiperidine-based drugs that target bacterial 
type II topoisomerases has been described. These drugs are known as “novel bacterial 
topoisomerase inhibitors” (NBTIs),26 one of which (GSK126)27 is shown in Figure 1. NBTIs 
differ from fluoroquinolones in three important respects. First, some members of this drug family 
do not enhance enzyme-mediated DNA cleavage (and therefore are not classified as gyrase 
“poisons”) and act strictly as catalytic inhibitors.12, 26, 28-30 Second, those NBTIs that do enhance 
DNA cleavage appear to stabilize primarily single-stranded (as opposed to double-stranded) 
DNA breaks generated by bacterial type II topoisomerases.12, 28, 30 Consistent with this 
observation, the crystal structure of a Staphylococcus aureus gyrase-DNA cleavage complex 
formed in the presence of the NBTI GSK299423 contains only one drug molecule (centrally 
located between the two scissile bonds), as compared to two (one at each scissile bond) for 
fluoroquinolones.26, 31 Third, NBTIs retain activity against cells that express clinically relevant 
mutations in gyrase or topoisomerase IV that are associated with fluoroquinolone resistance.26, 28-
30 In addition, while an S83L mutation in Escherichia coli GyrA increased the IC50 of 
ciprofloxacin from 0.35 µM to 15 µM, the activity of the NBTI GSK299423 was not altered by 
this mutation (IC50 ≈ 0.10 µM).26 Unfortunately, little else has been published regarding the 
actions of NBTIs against bacterial type II topoisomerases.  
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 NBTIs display relatively poor activity against M. tuberculosis gyrase.27 However, to develop 
NBTI-like drugs that act against tuberculosis, Blanco et al. used a high-throughput screen to 
identify a subclass of naphthyridone/aminopiperidine-containing compounds that displayed 
activity against M. tuberculosis cells in culture and the disease in mouse models.27 Due to 
structural and activity differences compared to NBTIs, compounds in this class are known as 
“Mycobacterium tuberculosis gyrase inhibitors” (MGIs). The MGIs are represented by GSK000 
and GSK325 in Figure 1. On the basis of genetic/mutagenesis studies in M. tuberculosis cells, 
the authors suggested that gyrase was the primary physiological target of MGIs.27 However, 
DNA cleavage studies with purified M. tuberculosis gyrase have yet to be reported for any MGI.  
 Given the potential clinical impact of MGIs for the treatment of tuberculosis, it is critical to 
understand how they interact with and affect the activity of their target. Therefore, we 
characterized the mechanism of action of MGIs against purified M. tuberculosis gyrase. GSK000 
and GSK325 were potent enhancers of gyrase-mediated DNA cleavage. In contrast to 
fluoroquinolones, the MGIs induced only single-stranded DNA breaks and suppressed the ability 
of gyrase to generate double-stranded breaks. Furthermore, they maintained activity against 
gyrase enzymes that harbored the three most common fluoroquinolone resistance mutations in 
tuberculosis and displayed no activity against human topoisomerase IIα. These findings provide 
critical mechanistic insight into the actions of MGIs against their cellular target and establish a 
framework for understanding their actions against tuberculosis.  
RESULTS AND DISCUSSION 
 MGIs Induce Gyrase-mediated Single-stranded DNA Breaks. Despite the fact that MGIs 
appear to target gyrase in M. tuberculosis cells,27 their effects on the DNA cleavage activity of 
the enzyme have yet to be characterized in vitro. Therefore, the effects of GSK000 and GSK325 
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on the DNA cleavage activity of purified M. tuberculosis gyrase were determined and compared 
to those of the NBTI GSK126. As seen in Figure 2, all three of the compounds increased levels 
of single-stranded, but not double-stranded DNA breaks. This is in contrast to the effects of 
moxifloxacin on M. tuberculosis gyrase, which induces primarily double-stranded breaks (Figure 
2, lower right gel). GSK000 was the most efficacious compound and increased levels of single-
stranded DNA breaks ~21-fold (from 2% cleavage at baseline to 42% maximal cleavage in the 
presence of the compound) as compared to GSK325 (~12.5-fold enhancement, 25% maximal 
cleavage) and GSK126 (~7.5-fold enhancement, 15% maximal cleavage) (Figure 2, left panel). 
These data are consistent with the previous cellular studies, which reported that GSK000 was 
more cytotoxic than GSK325 and that the NBTI GSK126 had little effect on the growth of M. 
tuberculosis cells.27 
 As a control, all three compounds were incubated with a negatively supercoiled plasmid in 
the absence of gyrase. Even at a concentration of 200 µM (a concentration 20-fold higher than 
needed to induce maximal DNA scission in the presence of enzyme), no enhancement of double-
stranded or single-stranded breaks was observed (Figure 2, lower right gel). Therefore, the DNA 
breaks observed in Figure 2 do not appear to be due to a chemical reaction between the 
MGIs/NBTI and DNA.  
 A number of experiments were carried out to further describe the enhancement of single-
stranded DNA cleavage by MGIs. Because GSK000 was the most efficacious compound, it was 
used as the focus for these studies. First, when DNA cleavage reactions were stopped by the 
addition of EDTA (which reverses gyrase-mediated cleavage by chelating the active-site divalent 
metal ions) or NaCl (which reverses cleavage by disrupting enzyme-DNA binding) prior to the 
addition of SDS (which traps DNA cleavage complexes by denaturing the enzyme), levels of 
single-stranded breaks generated in the presence of GSK000 dropped precipitously (Figure 3). 
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This finding confirms that DNA cleavage enhancement induced by the MGI was mediated by 
gyrase.  
 Second, some topoisomerase II poisons, such as the anti-cancer drug etoposide, generate 
primarily single-stranded breaks at low drug concentrations, but induce high levels of double-
stranded breaks at high concentrations.32-33 Presumably, this reflects the difficulty of a second 
drug molecule entering the DNA-cleavage complex. Therefore, to determine whether MGIs can 
also be pushed to induce double-stranded DNA breaks at high concentrations, a 60-min time 
course for gyrase-mediated DNA cleavage was carried out at 10 and 200 µM GSK000 (Figure 4, 
left panel). Similar results were observed under both conditions. Even at 200 µM drug over a 
time course (60 min) that was 6 times longer than used for standard DNA cleavage assays, no 
generation of double-stranded breaks was observed. Thus, it appears that GSK000 induces only 
gyrase-mediated single-stranded cleavage.  
 Third, even though gyrase does not require ATP to mediate either DNA cleavage or ligation, 
it needs the high-energy co-factor to carry out its complete DNA strand passage reaction.7, 10 The 
DNA cleavage reactions shown in Figures 2-4 were carried out in the absence of ATP. Thus, to 
determine whether the high-energy co-factor influences the ability of MGIs to induce single- vs. 
double-stranded DNA breaks, a titration of GSK000 (0-15 µM) was carried out in the absence or 
presence of 1 mM ATP. As seen in Figure 4 (right panel), ATP had no effect on the levels of 
single-stranded DNA cleavage or the ability of gyrase to induce double-stranded breaks.  
 Taken together, the above findings provide strong evidence that MGIs induce only single-
stranded DNA breaks mediated by M. tuberculosis gyrase.  
 GSK000 Acts by Stabilizing Cleavage Complexes Formed by M. tuberculosis Gyrase. 
Fluoroquinolone antibacterials increase levels of enzyme-mediated DNA strand breaks by 
stabilizing the covalent enzyme-DNA complexes that are formed upon scission of the genetic 
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material.6-12, 31, 34 These drugs do so by intercalating into the DNA at each of the cleaved scissile 
bonds, blocking the ability of gyrase to rejoin the newly generated DNA ends.10, 12, 26, 35-37 
However, only a single NBTI molecule (which is structurally related to the MGIs) appears to 
bind between the scissile bonds rather than intercalating within them and stretches the DNA.26-27 
Consequently, it is not obvious how MGIs increase levels of gyrase-mediated DNA strand 
breaks. To this point, DNA lesions increase topoisomerase II-mediated DNA cleavage by 
altering the structure of the genetic material within the cleavage site, allowing the enzyme to 
bend38 and cleave DNA faster.39-40 Therefore, two approaches were utilized to determine whether 
GSK000 alters the stability of cleavage complexes formed by M. tuberculosis gyrase. In both 
cases, the rate of loss of MGI-induced single-stranded DNA breaks was compared to the rate of 
loss of double-stranded breaks induced by the fluoroquinolone moxifloxacin.  
 As a first approach, we monitored the effects of GSK000 on the rate of enzyme-mediated 
DNA ligation, which was determined by shifting cleavage complexes from 37 ºC to 75 ºC (a 
temperature that allows ligation, but not cleavage of the DNA). As seen in Figure 5 (left panel), 
the rate of gyrase-mediated DNA ligation in the presence of 10 µM GSK000 was ~3 times 
slower than observed in the absence of drug. This diminution in the rate of ligation is similar to 
that seen in the presence 50 µM moxifloxacin and suggests that GSK000 stabilizes cleavage 
complexes to a similar extent as the fluoroquinolone.  
 For the second approach, we monitored the effects of GSK000 on the persistence (stability) 
of cleavage complexes following a 20-fold dilution of reaction mixtures. This assay is believed 
to reflect the rate at which the drug dissociates from the ternary complex, given that enzyme-
DNA-drug ternary complexes are much less likely to form when they are diluted. As seen in 
Figure 5 (right panel), GSK000 increased the lifetime of cleavage complexes to an extent even 
greater than that seen with moxifloxacin.  
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 Thus, it appears that GSK000 increases the level of gyrase-mediated single-stranded DNA 
breaks primarily by increasing the stability of cleavage complexes.  
 GSK000 and Moxifloxacin Induce Gyrase-mediated DNA Cleavage at a Different 
Array of Sites. Sites of gyrase-mediated DNA scission were mapped in the presence of GSK000 
or moxifloxacin to determine whether MGIs and fluoroquinolones display the same cleavage 
specificity (Figure 6). Linear end-labeled pBR322 was used for this experiment. Although 
overlap between the cleavage patterns generated by the MGI and the fluoroquinolone was 
observed (sites of similar cleavage are indicated by blue arrows), a number of unique sites or 
sites where utilization differed between the two drugs were observed. Representative sites that 
were cleaved more frequently in the presence of the MGI (red arrows) or the fluoroquinolone 
(green arrows) are indicated. These differences likely reflect the difference in the way MGIs and 
fluoroquinolones interact with M. tuberculosis gyrase.  
 Similar DNA cleavage results were obtained when cleavage complexes were enriched by 
K+-SDS precipitation of the gyrase prior to treatment with Proteinase K and electrophoresis 
(Figure 6). This provides further evidence that the cleavage observed was mediated by gyrase.  
 GSK000 Suppresses Double-stranded DNA Breaks Generated by M. tuberculosis 
Gyrase. Previous studies have demonstrated that topoisomerase II poisons like etoposide are 
able to act independently at each scissile bond.32 Consequently, drug action on the Watson strand 
often has relatively little effect on levels of cleavage or rates of ligation on the Crick strand.32 
Because MGIs/NBTIs do not appear to interact with the individual scissile bonds on the Watson 
and Crick strands, it is not obvious whether their presence coordinately affects cleavage on both 
strands. Thus, these compounds may enhance cleavage on only one strand of the double helix 
without affecting the other. Alternatively, the propensity of MGIs to induce single-stranded 
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breaks suggests that they may suppress the ability of the enzyme to cut both strands of the 
double-helix.  
 The low level of double-stranded DNA breaks induced by M. tuberculosis gyrase in the 
absence of drugs makes it difficult to differentiate between these two possibilities. Therefore, 
MgCl2 in DNA cleavage reactions was replaced with CaCl2. This latter divalent metal ion can 
replace Mg2+ in the active site of type II topoisomerases.41 Although most properties of the DNA 
cleavage and ligation reactions remain unchanged, considerably higher levels of enzyme-
mediated double-stranded breaks are generated in the presence of Ca2+.31, 41 In the case of M. 
tuberculosis gyrase, background levels of enzyme-mediated double-stranded DNA cleavage 
increased to ~10% (from 2% in Mg2+).  
 As seen in Figure 7, GSK000 induced high levels of single-stranded DNA breaks in the 
presence of Ca2+. However, this enhancement of single-stranded DNA cleavage was 
accompanied by a decrease in double-stranded DNA-cleavage (a representative gel is shown at 
the top, with quantification shown in the bottom panel). This finding strongly suggests that the 
induction of cleavage by one MGI molecule actually suppresses cleavage of the second strand. 
The molecular basis for this property is not known. However, it likely results from a distortion of 
the DNA in the active site of the enzyme, similar to what is generated in the presence of 
NBTIs.26 
 The Actions of GSK000 and Moxifloxacin on the Induction of Cleavage by M. 
tuberculosis Gyrase Are Mutually Exclusive. Because of the mechanistic and structural 
differences between the MGIs and fluoroquinolones, it is not known whether they can 
simultaneously affect DNA cleavage activity of a single gyrase enzyme. As a first step toward 
addressing this issue, modeling studies were carried out to address whether it is theoretically 
possible to form ternary gyrase-DNA-drug structures that include both GSK000 and 
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moxifloxacin (Figure 8). On the basis of these studies, it does not seem possible for both drugs to 
interact simultaneously in the same ternary complex. NBTIs are believed to trap the enzyme in 
the CRsym conformation, in which only one compound can be accommodated within the DNA. 
In the model of the GSK000 complex (Figure 8B), which is in the CRsym conformation, the 
DNA is well ordered and there is no room at either cleavage site to accommodate an additional 
compound.42 The moxifloxacin structure (Figure 8A) is in an intermediate conformation in which 
the subunits have moved slightly apart allowing a second compound to be accommodated in the 
DNA.42 Note that the superimposition of the GSK000 and moxifloxacin structures (Figure 8C) 
requires that basepairs overlap with the compounds. 
 To confirm the conclusions of the modeling studies, a competition study was utilized to 
determine whether GSK000 and moxifloxacin are capable of acting within the same ternary 
complex. In the absence of the MGI, moxifloxacin readily induced enzyme-mediated double-
stranded DNA breaks (~36% in the presence of 100 µM drug), but also induced ~12% single-
stranded breaks (peaking at 25 µM) (Figure 9, left panel). In the competition study, M. 
tuberculosis gyrase was saturated with 10 µM GSK000 (yielding the typical ~40% single-
stranded DNA breaks) (Figure 9, right panel) followed by incubation with 0-200 µM 
moxifloxacin. Changes in the level of double- and single-stranded breaks were monitored 
(Figure 9, right panel) to determine if there was competition or additivity between the two 
compounds. As the concentration of moxifloxacin increased, levels of double-stranded breaks 
rose, albeit to a lesser extent than seen in the absence of the MGI (similar changes in DNA 
cleavage were observed if gyrase was incubated with moxifloxacin prior to the addition of 
GSK000). Because GSK000 does not generate double-stranded DNA breaks, this increase 
demonstrates that the fluoroquinolone was able to stabilize cleavage complexes in reaction 
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mixtures that also contain the MGI. However, it does not differentiate whether the GSK000 in 
reaction mixtures was replaced by moxifloxacin or was still situated within the ternary complex. 
 To distinguish between these latter possibilities, we monitored the single-stranded breaks 
that are generated in the presence of both drugs (Figure 9, right panel). In contrast to double-
stranded breaks, single-stranded breaks decreased in the presence of moxifloxacin. This finding 
suggests that moxifloxacin acts only when it can displace GSK000 from the complex. Had both 
drugs been present in the ternary complex, levels of single-stranded breaks would have been 
expected to rise, because both drugs induce enzyme-mediated single-stranded DNA cleavage. 
Taken together, these results strongly suggest that the actions of MGIs and fluoroquinolones 
utilize mutually exclusive mechanisms to induce M. tuberculosis gyrase-mediated DNA 
cleavage.  
 GSK000 Induces Lower Levels of Gyrase-mediated DNA Cleavage on Positively 
Supercoiled DNA. In the cell, gyrase removes the positive supercoils that accumulate ahead of 
replication forks and transcription complexes.13, 18, 22 As these DNA tracking systems encounter 
the acting gyrase, transient cleavage complexes can be converted to non-ligatable DNA strand 
breaks that induce the SOS DNA damage response pathway.43 When this pathway is 
overwhelmed, the DNA breaks can lead to cell death. Because drug-stabilized cleavage 
complexes formed ahead of moving forks and transcription complexes are most likely to be 
converted to non-ligatable strand breaks, cleavage complexes stabilized on positively supercoiled 
DNA are the most dangerous for the cell.44-47 A recent study by Ashley et al. demonstrated that 
M. tuberculosis gyrase maintains 2-3-fold lower levels of cleavage complexes on positively 
compared to negatively supercoiled DNA in the absence or presence of fluoroquinolones.48 This 
attribute makes gyrase a safer enzyme (for cells) to work ahead of DNA tracking systems, but 
may also affect the cytotoxicity of fluoroquinolones.  
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 Because MGIs/NBTIs interact differently with DNA within the cleavage complex than do 
fluoroquinolones, we wanted to determine whether GSK000 differentially affected DNA scission 
mediated by M. tuberculosis gyrase on negatively and positively supercoiled substrates. As seen 
in Figure 10, gyrase induced ~3-4-fold lower levels of single-stranded breaks with positively 
supercoiled DNA. Thus, the effects of DNA supercoil geometry on the actions of MGIs and 
fluoroquinolones appear to be similar.  
 Effects of GSK000 on the Catalytic Activities of M. tuberculosis Gyrase. Some NBTIs 
appear to act by inhibiting the catalytic activities of bacterial type II topoisomerases rather than 
by poisoning these enzymes.12, 26, 28-30 In addition, the MGIs have been shown to inhibit the DNA 
supercoiling reaction catalyzed by M. tuberculosis gyrase.27 Therefore, the effects of GSK000 on 
the catalytic activities of M. tuberculosis gyrase were assessed and compared to those of 
moxifloxacin.  
 As seen in Figure 11 (top left and right panels), the IC50 values (~0.5 vs. 1 µM, respectively) 
for the inhibition of gyrase-catalyzed supercoiling of relaxed DNA by GSK000 and moxifloxacin 
were similar. This is in contrast to their abilities to kill M. tuberculosis cells27 or enhance DNA 
cleavage mediated by M. tuberculosis gyrase (see Figures 2 and 9). In these latter two cases, 
GSK000 is ≥10-fold more potent than moxifloxacin. These data strongly suggest that the 
mechanism of cell killing by these two drugs is not directly associated with their ability to inhibit 
DNA supercoiling catalyzed by M. tuberculosis gyrase.  
 In contrast to drug effects on DNA supercoiling, GSK000 was a more potent inhibitor of the 
gyrase-catalyzed relaxation of positively supercoiled DNA than was moxifloxacin (Figure 11, 
bottom left and right panels). The IC50 of the MGI (~2.5 to 5 µM) was at least an order of 
magnitude lower than that seen with moxifloxacin. The removal of positive DNA supercoils 
generated by replication forks represents a critical step in the elongation of DNA replication. 
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Therefore, these results cannot rule out a role for the inhibition of gyrase-catalyzed removal of 
positive supercoils (in addition to their effects on gyrase-mediated DNA cleavage) in cell death 
induced by MGIs.  
 GSK000 Preferentially Acts Against M. tuberculosis Gyrase. MGIs were originally 
selected for their ability to kill M. tuberculosis cells.27 However, it is not known whether the 
activity of MGIs toward this species reflects a broadened spectrum of drug activity or an 
increased specificity for M. tuberculosis. Therefore, the ability of GSK000 to induce DNA 
cleavage mediated by gyrase and topoisomerase IV from Gram-negative E. coli and Neisseria 
gonorrhoeae, and Gram-positive Bacillus anthracis was assessed (Figure 12). GSK000 displayed 
much lower activity against enzymes from these other species than it did for M. tuberculosis 
gyrase. Therefore, at least in regard to the interaction of MGIs with their enzyme target, it 
appears that the structural differences between MGIs and NBTIs increase the specificity of these 
drugs for M. tuberculosis gyrase rather than broadening their spectrum of action.  
 In order to extend this conclusion from biochemical studies to the organismal level, it will 
be necessary to carry out extensive microbiological studies on a variety of bacterial species. 
However, a comparison of the activity of GSK000, GSK325, and GSK126 toward cultured M. 
tuberculosis (H37Rv) and E. coli (7623) cells is consistent with an enhanced specificity of MGIs 
toward M. tuberculosis. Whereas, the reported MIC values of GSK000 and GSK325 for M. 
tuberculosis were <0.01 µM and 0.08 µM, respectively, the MIC for the NBTI GSK126 was 
considerably higher (0.5 µM).27 In contrast, for E. coli, the MIC of GSK126 (0.26 µM) was 
substantially lower than those of the two MGIs GSK000 and GSK325 (2.2 µM and 2.3 µM, 
respectively). It is also notable that the MICs for GSK000 and GSK325 against E. coli are 
considerably higher than those reported with M. tuberculosis.  
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 If the biochemical and microbiological data described above are representative of other 
species, an enhanced specificity of MGIs could have advantages for its clinical use. Tuberculosis 
is sometimes misdiagnosed as pneumonia, which is treated with fluoroquinolones.49-50 
Unfortunately, this initial treatment is associated with the development of fluoroquinolone-
resistant M. tuberculosis.50-53 If MGIs display specificity for M. tuberculosis, they would not be 
used to treat a misdiagnosed patient, potentially leading to fewer cases of resistance. In addition, 
anti-tuberculosis regimens are normally prescribed for several months.4-5 Thus, patients taking 
MGIs are potentially less likely to incur the adverse drug events associated with the long-term 
use of a broad-spectrum antibacterial in the regimen.1 
 MGIs share two properties with fluoroquinolones that may ultimately affect their clinical 
development. First, the MGIs inhibition of the hERG potassium channel may need to be 
decreased.27 Second, the reported frequency of spontaneous resistance mutations for GSK126 
(no data is available for the MGIs) is higher than that of moxifloxacin.27 However, this value is 
similar to or lower than other drugs routinely used to treat tuberculosis.  
 MGIs Maintain Activity Against M. tuberculosis Gyrase Enzymes Carrying the Most 
Common Mutations Associated with Fluoroquinolone Resistance. In a previous study, 
GSK000 and GSK325 maintained cytotoxic activity against M. tuberculosis cells that carried 
gyrase mutations GyrAA90V or GyrAD94G, both of which elicit fluoroquinolone resistance.27 
However, the effects of these two MGIs on the DNA cleavage activity of M. tuberculosis gyrase 
enzymes that harbor these fluoroquinolone resistance mutations are unknown. Therefore, the 
effects of GSK000 and GSK325, as well as GSK126, on gyrase enzymes containing the 
GyrAA90V or GyrAD94G mutations or a GyrAD94H mutation were determined. These three gyrase 
alterations represent the most common mutations associated with fluoroquinolone resistance in 
tuberculosis.9 
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 As seen in Figure 13, all three of the compounds retained the ability to induce the mutant 
gyrase enzymes to generate single-stranded DNA breaks. GSK000 retained full activity against 
all three mutant enzymes (left panel). Although the activity of GSK325 (middle panel) was 
slightly lower when incubated with GyrAD94H, the compound maintained full activity against 
GyrAA90V and GyrAD94G. If anything, GSK126 (right panel) displayed higher activity against 
GyrAA90V and GyrAD94G. These results demonstrate that MGIs and a related NBTI are able to 
overcome the most common causes of target-mediated fluoroquinolone resistance in 
tuberculosis.  
 We took advantage of these findings with the fluoroquinolone-resistant mutant enzymes to 
reexamine the moxifloxacin-GSK000 competition studies (Figure 9). In contrast to results with 
the wild-type enzyme, moxifloxacin was unable to compete with the actions of GSK000 against 
GyrAD94G (Figure 14). Even at 200 µM moxifloxacin, virtually no decrease in single-stranded 
breaks or increase in double-stranded breaks was observed. This finding confirms that the 
competition between moxifloxacin and GSK000 seen in Figure 9 was due to the replacement of 
the MGI by the fluoroquinolone in the active site of gyrase. 
 MGIs Do Not Induce DNA Cleavage Mediated by Human Topoisomerase IIα . 
Bacterial and human type II topoisomerases share a significant level of amino acid identity.15 
Although clinically relevant fluoroquinolone antibacterials display low activity against the 
human type II enzymes, some members of this drug class cross over into mammalian systems 
and are potent poisons of human type II topoisomerases.7, 10, 54-56 Because poisoning the human 
enzyme precludes the clinical use of these fluoroquinolones as antibacterial agents, it is 
important to assess the activity of gyrase-targeted drugs against the human enzymes.  
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 The ability of GSK000 and GSK325, as well as the NBTI GSK126, to induce DNA strand 
breaks mediated by topoisomerase IIα is shown in Figure 15. None of the drugs displayed any 
effect on DNA cleavage mediated by the human enzyme. This result is in marked contrast to the 
high levels of single- and double-stranded breaks induced by etoposide, a clinically important 
anti-cancer drug.32, 57  
 Conclusions. Tuberculosis is one of the leading causes of morbidity worldwide and drug 
resistance and intolerance are prevalent. Consequently, there is a desperate need for the 
development of new anti-tubercular drugs that overcome resistance and/or are better tolerated by 
patients. Although there is a continual search for new drug targets, another approach is to 
develop novel compounds with high activity against validated targets, but that still retain activity 
in the face of current resistance profiles. 
 MGIs were selected for activity against M. tuberculosis, and, based on genetic studies and 
their structural similarities to NBTIs, they were believed to target gyrase.27 However, little was 
known about their interactions with the M. tuberculosis type II enzyme. Therefore, we 
characterized the activity of two MGIs against M. tuberculosis gyrase. Results indicate that 
MGIs are potent gyrase poisons. These compounds induce only single-stranded enzyme-
mediated DNA breaks and suppress the ability of gyrase to cut both strands of the double helix. 
MGIs appear to be selective for M. tuberculosis gyrase over other species, retain activity against 
the most common mutations that lead to fluoroquinolone resistance, and display no activity 
against human topoisomerase IIα. These findings suggest that MGIs have potential as anti-
tubercular drugs, especially in the case of fluoroquinolone-resistant disease. The mechanistic 
studies described above provide a basis for future structure-activity studies directed toward 
improving drug activity, while addressing physiological toxicities and mutation rates.  
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METHODS 
Enzymes and Materials. Full-length wild-type M. tuberculosis gyrase subunits (GyrA and 
GyrB) and GyrA mutants (GyrAA90V, GyrAD94H, and GyrAD94G) were expressed and purified as 
described previously.31 E. coli topisomerase IV was provided by Keir C. Neuman (National 
Heart, Lung, and Blood Institute at National Institutes of Health). B. anthracis gyrase was 
expressed and purified by Rachel E. Ashley as described previously.58 B. anthracis 
topoisomerase IV was expressed and purified as described previously.58 The N. gonorrhoeae 
enzymes and E. coli gyrase were provided by Pan Chan (GlaxoSmithKline). Human 
topoisomerase IIα was expressed in yeast and purified as described by Kingma et al.59 
Negatively supercoiled pBR322 DNA was prepared from E. coli using a Plasmid Mega Kit 
(Qiagen) as described by the manufacturer. Positively supercoiled pBR322 DNA was prepared 
by treating negatively supercoiled molecules with recombinant Archaeoglobus fulgidus reverse 
gyrase.60-61 The number of positive supercoils induced by this process is comparable to the 
number of negative supercoils in the original pBR322 preparations.60 In the experiments that 
compared negatively and positively supercoiled DNA, the negatively supercoiled plasmid 
preparations were processed identically to the positively supercoiled molecules except that 
reaction mixtures did not contain reverse gyrase. Relaxed pBR322 plasmid DNA was generated 
by treating negatively supercoiled pBR322 with calf thymus topoisomerase I (Invitrogen) and 
purified as described previously.62 
The MGIs GSK000 and GSK325 and the NBTI GSK126 were synthesized as described 
previously by Blanco et al.27 In the paper by Blanco et al., GSK126, GSK325, and GSK000 were 
identified as compounds 1, 2, and 3, respectively. Moxifloxacin was obtained from LKT 
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Laboratories. The MGIs and moxifloxacin were stored at 4 ºC as 20 mM stock solutions in 100% 
dimethylsulfoxide.  
Molecular Modeling. The structure of GSK000 in a ternary complex with M. tuberculosis 
gyrase was modeled using Coot,63 MOE,64 and Maestro (Schrödinger Release 2017-2: Maestro, 
Schrödinger, LLC, New York, NY, 2017). Drug placement was based on the crystal structure of 
the NBTI GSK299423 in a ternary complex with Staphylococcus aureus gyrase [Protein Data 
Bank (PDB) code 2XCS] and the crystal structure of a cleavage complex of M. tuberculosis 
gyrase with moxifloxacin (PDB code 5BTA).  
  DNA Cleavage. DNA cleavage reactions were based on the procedure of Aldred et al.55 
Reactions were carried out in the presence or absence of MGIs/NBTI or moxifloxacin and 
contained 100 nM wild-type or mutant (GyrAA90V, GyrAD94H, and GyrAD94G) gyrase (2:1 
GyrA:GyrB ratio) and 10 nM positively or negatively supercoiled pBR322 in a total volume of 
20 μL of cleavage buffer [10 mM Tris-HCl (pH 7.5), 40 mM KCl, 6 mM MgCl2, 0.1 mg/mL 
bovine serum albumin, and 10% glycerol]. In some cases, 1 mM ATP was included in reaction 
mixtures, or the MgCl2 in the cleavage buffer was replaced with 6 mM CaCl2 or. Unless stated 
otherwise, reactions were incubated at 37 ºC for 10 min. Enzyme-DNA cleavage complexes were 
trapped by adding 2 µL of 5% sodium dodecyl sulfate followed by 2 μL of 250 mM Na2EDTA 
and 2 µL of 0.8 mg/mL Proteinase K (Sigma Aldrich). Reaction mixtures were incubated at 45 
ºC for 30 min to digest the topoisomerases. Samples were mixed with 2 µL of 60% sucrose, 10 
mM Tris-HCl (pH 7.9), 0.5% bromophenol blue; and 0.5% xylene cyanol FF and were incubated 
at 45 ºC for 2 min before loading onto 1% agarose gels. Reaction products were subjected to 
electrophoresis in a buffer of 40 mM Tris-acetate (pH 8.3) and 2 mM EDTA that contained 0.5 
µg/mL ethidium bromide. DNA bands were visualized with medium-range ultraviolet light and 
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quantified using an Alpha Innotech digital imaging system. DNA single- or double-stranded 
cleavage was monitored by the conversion of supercoiled plasmid to nicked or linear molecules, 
respectively and quantified in comparison to a control reaction in which an equal amount of 
DNA was digested by EcoRI (New England BioLabs).  
 DNA cleavage reactions with human topoisomerase IIα were performed as described 
previously.65 Reaction mixtures contained 150 nM topoisomerase IIα and 10 nM negatively 
supercoiled pBR322 DNA in 20 µL of 10 mM Tris-HCl (pH 7.9), 5 mM MgCl2, 100 mM KCl, 
0.1 mM EDTA, and 2.5% (v/v) glycerol. Reaction mixtures were incubated for 6 min at 37 °C. 
Enzyme-DNA cleavage complexes were trapped, processed, subjected to electrophoresis, and 
DNA cleavage bands were visualized and quantified as described above.  
 DNA Ligation. DNA ligation assays were carried out in the absence or presence of 
GSK000 or moxifloxacin following the procedure of Robinson and Osheroff.66 Reaction 
mixtures (20 µL) contained 100 nM wild-type M. tuberculosis gyrase and 10 nM negatively 
supercoiled pBR322 in cleavage buffer. In experiments carried out in the absence of drug, MgCl2 
in the cleavage buffer was replaced with 6 mM CaCl2 to increase baseline levels of DNA 
cleavage. DNA cleavage–religation equilibria were established at 37 °C for 10 min. Ligation was 
initiated by shifting the samples from 37 °C to 75 °C. Reactions were stopped at times ranging 
from 0 to 210 s by the addition of 2 µL of 5% SDS followed by 2 µL of 250 mM EDTA (pH 
8.0). Samples were digested with Proteinase K, processed, and visualized as described above. 
Levels of MGI-induced single-stranded and moxifloxacin induced double-stranded DNA 
cleavage were set to 1 at 0 s, and ligation was assessed by the loss of nicked or linear reaction 
product, respectively, over time. 
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 Persistence of Gyrase-DNA Cleavage Complexes. The persistence of gyrase-DNA 
cleavage complexes in the absence or presence of GSK000 or moxifloxacin was determined 
using the procedure of Aldred et al.55 Initial reaction mixtures contained 500 nM gyrase, 50 nM 
negatively supercoiled pBR322, and 10 µM GSK000 or 50 µM moxifloxacin in cleavage buffer 
a total volume of 20 µL. In experiments carried out in the absence of drug, the MgCl2 in the 
cleavage buffer was replaced with 6 mM CaCl2 to increase baseline levels of DNA cleavage. 
Reaction mixtures were incubated at 37 ºC for 10 min to allow cleavage complexes to form, and 
were then diluted 20–fold with 1X reaction buffer warmed to 37 ºC. Samples (20 µL) were 
removed at times ranging from 0–240 min. DNA cleavage was stopped and samples were 
digested with Proteinase K, processed, and visualized as described above. Levels of MGI-
induced single-stranded and moxifloxacin-induced double-stranded DNA cleavage were set to 1 
at time zero, and the persistence (stability) of cleavage complexes was determined by the loss of 
single- or double-stranded DNA cleavage, respectively, over time. 
 DNA Cleavage Site Utilization. DNA cleavage sites were mapped using a modification67 of 
the procedure of O’Reilly and Kreuzer.68 The pBR322 DNA substrate was linearized by 
treatment with HindIII. Terminal 5′-phosphates were removed by treatment with calf intestinal 
alkaline phosphatase and were replaced with [32P]phosphate using T4 polynucleotide kinase and 
[γ-32P]ATP. The DNA was then treated with EcoRI, and the 4332-base pair singly end-labeled 
fragment was purified from the small EcoRI–HindIII fragment by passing it through a 
CHROMA SPIN+TE-100 column (Clontech). Reaction mixtures contained 500 nM wild-type M. 
tuberculosis gyrase and 5 nM radiolabeled pBR322 DNA substrate in 50 μL of DNA cleavage 
buffer with 6 mM CaCl2 in the absence or presence of MGIs or moxifloxacin. Reaction mixtures 
were incubated at 37 °C for 10 min, and enzyme-DNA cleavage complexes were trapped by the 
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addition of 5 μL of 10% SDS followed by 3 μL of 250 mM EDTA (pH 8.0). Proteinase K (5 μL 
of a 0.8 mg/mL solution) was added, and samples were incubated at 45 °C for 30 min to digest 
the enzyme. Alternatively, cleavage complexes were enriched by K+-SDS precipitation of gyrase, 
prior to Proteinase K treatment.69 This was accomplished by adding 25 µL of 2.5 M KCl and 
incubating at -20 °C for 10 min. Mixtures were centrifuged at 18,000 x g for 10 min. Pellets were 
resuspended in 50 µL of 10 mM Tris-borate (pH 7.9) and 1 mM EDTA and were then treated 
with Proteinase K as described above. In both cases, DNA products were precipitated with 
ethanol and resuspended in 6 μL of 40% formamide, 10 mM NaOH, 0.02% bromophenol blue, 
and 0.02% xylene cyanol FF. Samples were heated at 75 °C for 2 min and were subjected to 
electrophoresis in a denaturing 6% polyacrylamide sequencing gel in 100 mM Tris-borate (pH 
8.3) and 2 mM EDTA. Gels were dried in vacuo, and DNA cleavage products were visualized 
with a Bio-Rad Molecular Imager FX. 
 DNA Supercoiling and Relaxation. DNA supercoiling/relaxation assays were based on 
previously published protocols.31, 55 Assays contained 75 nM gyrase (1.5:1 GyrA:GyrB ratio), 5 
nM relaxed or positively supercoiled pBR322, 1.5 mM ATP, and 1 mM DTT in 20 μL of 10 mM 
Tris-HCl (pH 7.5), 80 mM KCl, 6 mM MgCl2, 0.1 mg/mL BSA, and 10 % glycerol. Reactions 
were incubated at 37 °C for 30 min (DNA supercoiling assays) or 1 min (DNA relaxation 
assays). The chosen assay lengths represent the minimum time required to completely supercoil 
or relax the DNA in the absence of drug. Reaction mixtures were stopped by the addition of 3 µL 
of a mixture of 0.77% SDS and 77.5 mM Na2EDTA. Samples were mixed with 2 µL of 60% 
sucrose, 10 mM Tris-HCl (pH 7.9), 0.5% bromophenol blue, and 0.5% xylene cyanol FF and 
were incubated at 45 ºC for 2 min before loading onto 1% agarose gels in 100 mM Tris-borate 
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(pH 8.3) and 2 mM EDTA. Gels were stained with 1 µg/mL ethidium bromide for 30 min. DNA 
bands were visualized with medium-range ultraviolet light as described above. 
 Determination of Minimum Inhibitory Concentrations (MICs). MIC values for GSK000, 
GSK325, and GSK126 against cultured E. coli (7623) cells were determined as described in 
Blanco, et al. 27  
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Figure 1. Structures of selected compounds that alter the activity of gyrase. GSK000 and 
GSK325 are Mycobacterium tuberculosis Gyrase Inhibitors (MGIs); GSK 126 is a Novel 
Bacterial Topoisomerase Inhibitor (NBTI); and moxifloxacin is a fluoroquinolone antibacterial. 
Figure 2. MGIs induce single-stranded DNA breaks mediated by M. tuberculosis gyrase. The 
left panel shows the quantification of single-stranded (SS, closed circles) and double-stranded 
(DS, open circles) DNA breaks induced by GSK000 (red), GSK325 (blue), or GSK126 (black) in 
the presence of M. tuberculosis gyrase. Error bars represent the standard deviation (SD) of four 
independent experiments. The top right gel shows DNA cleavage products produced by gyrase 
that was incubated with increasing concentrations of GSK000. The bottom right gel shows DNA 
products following cleavage reactions containing 10 µM GSK000 (000), GSK325 (325), or 
GSK126 (126), or 20 µM moxifloxacin (Moxi) in the presence of gyrase or 200 µM GSK000, 
GSK325, or GSK126 in the absence of enzyme. Negatively supercoiled (SC) and linear (Lin) 
DNA controls are shown along with a reaction that contained gyrase, but no drug (Gyr). The 
mobilities of negatively supercoiled DNA [(-)SC], nicked circular DNA (Nick), and linear DNA 
(Lin) are indicated. Gels are representative of at least four independent experiments.  
Figure 3. DNA cleavage induced by GSK000 is mediated by M. tuberculosis gyrase. The bar 
graph shows results from reactions that contained negatively supercoiled DNA in the presence of 
M. tuberculosis gyrase (Gyr, black bar), GSK000 (200 µM) in the absence of gyrase (GSK000), 
or complete reaction mixtures containing 10 µM GSK000 and gyrase that were stopped with 
SDS prior to the addition of EDTA (blue bar), and reactions that were treated with EDTA (green 
bar) or NaCl (yellow bar) prior to SDS. Error bars represent the SD of at least 4 independent 
experiments. 
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Figure 4. GSK000 enhances only single-stranded DNA breaks mediated by M. tuberculosis 
gyrase. The panel on the left shows the enhancement of gyrase-mediated single-stranded (SS, 
closed circles) or double-stranded (DS, open circles) DNA breaks generated by gyrase over time 
in reactions that contained 10 µM (red) or 200 µM (black) GSK000. The right panel shows the 
effects of GSK000 on gyrase-mediated DNA cleavage in the presence (red) or absence (black) of 
ATP (1 mM). Error bars represent the SD of at least 3 independent experiments. 
Figure 5. Effects of GSK000 and moxifloxacin on ligation and persistence of cleavage 
complexes mediated by M. tuberculosis gyrase. The rate of gyrase-mediated DNA ligation (left) 
and the stability of ternary gyrase–drug–DNA cleavage complexes (right) were monitored by the 
loss of single-stranded DNA breaks in the presence of 10 µM GSK000 (red) or the loss of 
double-stranded DNA cleavage in the absence of drug (black) or in the presence of 50 µM 
moxifloxacin (blue). Levels of DNA cleavage at time 0 (42% single-stranded breaks in the 
presence of GSK000 and 36% double-stranded breaks in the presence of moxifloxacin) were set 
to 1 to allow direct comparison. Error bars represent the SD of at least 3 independent 
experiments. 
Figure 6. Effects of GSK000 and moxifloxacin on the sites of DNA cleavage generated by M. 
tuberculosis gyrase. An autoradiogram of a polyacrylamide gel is shown. Reaction mixtures 
contained DNA with no enzyme (DNA), enzyme in the absence of drug (Gyr), or enzyme in the 
presence of 100 µM GSK000 (GSK000) or 100 µM moxifloxacin (Moxi). The left- and right-
hand sides of the gel show reactions processed without or following K+-SDS precipitation of 
DNA cleavage complexes. Red arrows indicate representative strong sites where GSK000 
induced greater levels of DNA cleavage than did moxifloxacin, green arrows indicate 
representative strong sites where moxifloxacin induced greater levels of cleavage than did 
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GSK000, and blue arrows indicate representative sites where GSK000 and moxifloxacin induced 
similar levels of cleavage. The autoradiogram is representative of at least 4 independent 
experiments.  
Figure 7. GSK000 suppresses double-stranded DNA breaks generated by M. tuberculosis 
gyrase. The gel (top) shows DNA cleavage products following incubation of gyrase with 
increasing concentrations of GSK000 in the presence of Ca2+. Negatively supercoiled (SC) and 
linear controls (Lin) are shown. The gel is representative of at least 4 independent experiments. 
The graph quantifies the effects of GSK000 on M. tuberculosis gyrase-mediated single-stranded 
(SS, closed circles) and double-stranded (DS, open circles) DNA cleavage. Error bars represent 
the SD of at least 4 independent experiments.  
Figure 8. Modeling studies suggest that moxifloxacin and GSK000 cannot interact 
simultaneously in the same drug-enzyme-DNA ternary complex. A. View down the two-fold 
axis of a crystal structure of a ternary complex formed with M. tuberculosis gyrase, DNA, and 
moxifloxacin.35 Gyrase subunits are shown in cartoon representation, in blue/cyan (GyrA) or 
red/dark red (GyrB). The catalytic tyrosine (Tyr 129) which has cleaved the DNA is shown in 
stick representation. Moxifloxacin (orange carbons) and DNA (green carbons) are also shown in 
stick representation. B. Model of a complex of GSK000 (yellow carbons) with M. tuberculosis 
gyrase and uncleaved DNA that was based on the crystal structure of GSK299423 with 
Staphylococcus aureus gyrase.26 C. Superimposition of A and B require that base-pairs overlap 
with the compounds.  
Figure 9. The actions of GSK000 and moxifloxacin on gyrase-mediated DNA cleavage are 
mutually exclusive. In the left panel, enhancement of M. tuberculosis gyrase-mediated single-
stranded (SS, closed circles) and double-stranded (DS, open circles) DNA cleavage is shown in 
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the presence of moxifloxacin alone (blue). In the right panel, gyrase was saturated with 10 µM 
GSK000 followed by a subsequent titration of 0-200 µM moxifloxacin. Error bars represent the 
SD of at least 3 independent experiments.  
Figure 10. GSK000 maintains lower levels of gyrase-mediated single-stranded DNA breaks on 
positively supercoiled DNA. The effects of GSK000 on the enhancement of gyrase-mediated 
single-stranded cleavage of negatively (closed circles) and positively (open circles) supercoiled 
DNA is shown. Error bars represent the SD of at least 3 independent experiments.  
Figure 11. Inhibition of gyrase catalyzed reactions by GSK000 and moxifloxacin. The effects of 
GSK000 (left panels) and moxifloxacin (right panels) on the supercoiling of relaxed DNA (top 
panels) and the relaxation of positively supercoiled DNA (bottom panels) are shown. The 
positions of relaxed (Rel), negatively supercoiled [(-)SC], and positively supercoiled [(+)SC] 
DNA are indicated. Gels are representative of at least four independent experiments. 
Figure 12. GSK000 acts preferentially against M. tuberculosis gyrase. The effects of GSK000 on 
single-stranded DNA cleavage mediated by M. tuberculosis gyrase (Mt gyr, red), B. anthracis 
gyrase (Ba gyr, purple) and topoisomerase IV (Ba TIV, blue), N. gonorrhoeae gyrase (Ng gyr, 
green) and topoisomerase IV (Ng TIV, yellow), and E. coli gyrase (Ec gyr, orange) and 
topoisomerase IV (Ec TIV, black) are shown. Error bars represent the SD of at least 3 
independent experiments. 
Figure 13. MGIs/NBTI maintain activity against M. tuberculosis gyrase containing the most 
common mutations associated with clinical fluoroquinolone resistance. Effects of the MGIs 
GSK000 (left panel), GSK325 (middle panel), and the NBTI GSK126 (right panel) on wild-type 
(red) M. tuberculosis gyrase and gyrase containing the fluoroquinolone resistance mutations at 
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GyrAA90V (blue), GyrAD94G (purple), or GyrAD94H (green) are shown. Single-stranded (SS) and 
double-stranded (DS) DNA breaks are denoted by closed and open circles respectively. Error 
bars represent the SD of at least 3 independent experiments.  
Figure 14. The actions of GSK000 and moxifloxacin on DNA cleavage mediated by GyrAD94G. 
The mutant fluoroquinolone-resistant gyrase was saturated with 10 µM GSK000 followed by a 
subsequent titration of 0-200 µM moxifloxacin. Error bars represent the SD of at least 3 
independent experiments.  
Figure 15. MGIs/NBTI do not enhance DNA cleavage mediated by human topoisomerase IIα. 
The left and right panels show the effects of the MGIs GSK000 (red) and GSK325 (blue) and the 
NBTI GSK126 (black) on single-stranded (closed circles) and double-stranded (open circles) 
DNA cleavage mediated by the human enzyme. The effects of etoposide (green), a widely 
prescribed anti-cancer drug, on topoisomerase IIα are shown as a positive control. Error bars 
represent the SD of at least 3 independent experiments. 
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